[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ferrer Internacional S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100554459","treprostinil-in-newborns-with-pulmonary-hypertension-a-non-interventional-study-to-collect-data-on-drug-utilization-safety-and-effectiveness-100554459",false,"NCT06499363","Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness","Treprostinil in Newborns With Pulmonary Hypertension; a Noninterventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness.","NEPHY","Inclusion Criteria:\n\n1. Newborn infants who received at least one dose of IV or SC treprostinil as per clinical practice within 5 years from the moment of data collection.\n2. Aged up to 44 weeks after conception at treprostinil initiation.\n3. Pulmonary hypertension (PH) or suspicion of PH at the moment of treprostinil initiation.\n4. Parent(s) or legally authorized representative(s) provides non-opposition consent for the patient participation in the study.\n5. Newborn infants affiliated to French social security.\n\nExclusion Criteria:\n\n* None.","ALL","44 Weeks",{"count":20,"type":21},60,"ESTIMATED","OBSERVATIONAL","This observational study will seek to describe the uses and safety and efficacy outcomes of treprostinil in clinical practice in patients with persistent pulmonary hypertension (PPHN).",[25],"Persistent Pulmonary Hypertension of Newborn","RECRUITING","2025-09-02",{"date":29,"type":30},"2025-09-03","ACTUAL",{"date":32,"type":30},"2025-02-25",{"date":34,"type":21},"2027-12-31",{"name":36,"class":37},"Ferrer Internacional S.A.","INDUSTRY",4,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":4,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":17,"minAge":45,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":46,"phases":4,"briefSummary":47,"conditions":48,"keywords":52,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":66,"locationsCount":4},"100483281","inhaled-treprostinil-expanded-access-program-in-pulmonary-hypertension-associated-with-interstitial-lung-disease-100483281","NCT05572996","Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n1. Patient consent\n2. Males and females aged 18 years old or older\n3. PH-ILD diagnosis:\n\n   * Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC):\n\n     \\- mPAP \\> 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and\n   * Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)\n\nExclusion Criteria:\n\n1. Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD\n2. Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat)\n3. Use of any concomitant investigational drug","18 Years","EXPANDED_ACCESS","This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.",[49,50,51],"Pulmonary Hypertension","Interstitial Lung Disease","Combined Pulmonary Fibrosis and Emphysema",[53,54,55,56,57,58,59,60,61],"Inhaled Treprostinil","Tyvaso","EAP","Expanded Access","Early Access","Compassionate Use","Named Patient Program","NPP","PH-ILD","AVAILABLE","2022-10-05",{"date":65,"type":30},"2022-10-10",{"name":36,"class":37},""]